Almirall, S.A. (LON:0O9B)

London flag London · Delayed Price · Currency is GBP · Price in EUR
13.50
+0.22 (1.66%)
At close: Feb 11, 2026
Market Cap2.50B +48.3%
Revenue (ttm)947.08M +13.8%
Net Income36.70M
EPS0.17
Shares Outn/a
PE Ratio68.11
Forward PE33.82
Dividend0.13 (0.95%)
Ex-Dividend DateMay 15, 2025
Volume676
Average Volume6,427
Open13.16
Previous Close13.28
Day's Range13.20 - 13.68
52-Week Range8.74 - 13.64
Beta0.17
RSI59.66
Earnings DateFeb 23, 2026

About Almirall

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, nervous, and respiratory system; dermatologicals; genito urinary system and sex hormones; immun... [Read more]

Industry Pharmaceutical Preparations
Founded 1943
Employees 2,084
Stock Exchange London Stock Exchange
Ticker Symbol 0O9B
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements